Loading organizations...
Loading organizations...

Lygos engineers yeast to convert sugar into high-value industrial…
Lygos has raised $33.5M across 3 funding rounds.
Lygos was founded in 2011 by Eric Steen (Founder/CSO).
Lygos has raised $33.5M in total across 3 funding rounds.
Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production.
Lygos was founded in 2011 by Eric Steen (Founder/CSO).
Lygos has raised $33.5M in total across 3 funding rounds.
Lygos's investors include LG Technology Ventures, First Round Capital, Brad Gillespie, OS Fund, Y Combinator, Jeffrey Klunzinger, Fifty Years, Vast Ventures.
Key people at Lygos.
Lygos is a biotechnology company that engineers yeast and other microbes to convert sugars into high-value, bio-based industrial chemicals, focusing on sustainable alternatives to petrochemical-derived products. Their mission is to create better-performing, cost-effective, and sustainable specialty chemicals that serve industries such as agronomy, home care, personal care, and water treatment. By integrating synthetic biology, chemistry, and engineering, Lygos develops biodegradable polymers and specialty materials that improve product performance while reducing environmental impact, supporting manufacturers and brands aiming for greener supply chains[1][4][5].
Founded in 2010 by experts including Jay D. Keasling, Lygos emerged from advances in synthetic biology and metabolic engineering to address the challenge of producing essential industrial chemicals more sustainably. The company’s early traction includes commercial adoption of products like Soltellus™, a specialty material applied on over 350,000 acres in agronomy within its first year, and integration into home care brands across North America. Lygos has evolved by leveraging partnerships and technology upgrades to accelerate microbial cell factory development and scale production efficiently[1][2][4].
Lygos rides the growing trend of bio-based industrial chemistry, driven by increasing demand for sustainable materials and regulatory pressures to reduce carbon footprints. The timing is favorable due to advances in synthetic biology, rising consumer preference for greener products, and the need to replace toxic or fossil-derived chemicals. Lygos influences the ecosystem by demonstrating that bio-manufactured specialty chemicals can outperform traditional petrochemical products economically and functionally, encouraging broader adoption of biotechnology in industrial manufacturing[1][3][4].
Looking ahead, Lygos is poised to expand its portfolio of bio-based specialty chemicals and deepen partnerships to scale production further. Trends such as AI-driven strain engineering, circular economy initiatives, and heightened sustainability mandates will shape their trajectory. Their pragmatic approach to integrating chemistry, biology, and supply chain expertise positions them to accelerate the transition from petrochemical to bio-based industrial chemicals, potentially becoming a key player in the global shift toward sustainable manufacturing[2][4].
In summary, Lygos exemplifies how engineered microbes can transform renewable sugars into high-value, sustainable chemicals that meet real industrial needs, combining innovation with scalability to drive impact across multiple sectors.
Lygos has raised $33.5M across 3 funding rounds. Most recently, it raised $5.0M Series B in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 23, 2019 | $5.0M Series B | LG Technology Ventures | |
| Jul 17, 2018 | $15.5M Series B | First Round Capital, Brad Gillespie | OS Fund, Y Combinator |
| Dec 13, 2016 | $13.0M Series A | Brad Gillespie, Jeffrey Klunzinger | Fifty Years, First Round Capital, Vast Ventures, Y Combinator |